TY - JOUR
T1 - Weight and leptin changes among risperidone-treated youths with autism
T2 - 6-Month prospective data
AU - Martín, Andrés
AU - Scahill, Lawrence
AU - Anderson, George M.
AU - Aman, Michael
AU - Arnold, L. Eugene
AU - McCracken, James
AU - McDougle, Christopher J.
AU - Tierney, Elaine
AU - Chuang, Shirley
AU - Vitiello, Benedetto
PY - 2004/6
Y1 - 2004/6
N2 - Objective: The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change. Method: Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months. Change in serum leptin levels after 2 months was examined as a predictor of final weight gain in mixed regression models that controlled for site, gender, age, and risperidone dose. Results: Age- and gender-standardized weight increased after 6 months of treatment (gross: mean=5.6 kg [SD=3.9]; standardized: mean=0.6 z [SD=0.5]) and was positively correlated with weight gained after 1 month. Change in leptin levels after 2 months of treatment (mean=-0.3 ng/ml, SD:6.2) (N=48) did not predict final weight gain. Conclusions: Chronic risperidone exposure in children with autism causes weight gain in excess of developmentally expected norms that follows a curvilinear trajectory and decelerates over time. Serum leptin change does not reliably predict risperidone-associated weight gain.
AB - Objective: The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change. Method: Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months. Change in serum leptin levels after 2 months was examined as a predictor of final weight gain in mixed regression models that controlled for site, gender, age, and risperidone dose. Results: Age- and gender-standardized weight increased after 6 months of treatment (gross: mean=5.6 kg [SD=3.9]; standardized: mean=0.6 z [SD=0.5]) and was positively correlated with weight gained after 1 month. Change in leptin levels after 2 months of treatment (mean=-0.3 ng/ml, SD:6.2) (N=48) did not predict final weight gain. Conclusions: Chronic risperidone exposure in children with autism causes weight gain in excess of developmentally expected norms that follows a curvilinear trajectory and decelerates over time. Serum leptin change does not reliably predict risperidone-associated weight gain.
UR - http://www.scopus.com/inward/record.url?scp=2942536152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942536152&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.161.6.1125
DO - 10.1176/appi.ajp.161.6.1125
M3 - Article
C2 - 15169706
AN - SCOPUS:2942536152
SN - 0002-953X
VL - 161
SP - 1125
EP - 1127
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 6
ER -